This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Chris Adair: Innovator in Pharmaceutical Chemistry
Introduction
Chris Adair is a notable inventor based in Brighton, MA (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds that target specific biological pathways. His work is characterized by a commitment to advancing medical science and improving patient outcomes.
Latest Patents
Chris Adair holds 1 patent for his invention titled "Tricyclic AKR1C3 dependent KARS inhibitors." This patent relates to innovative tricyclic compounds that act as AKR1C3 dependent KARS inhibitors. The invention encompasses processes for the preparation of these compounds, pharmaceutical compositions, and medicaments that contain them. Furthermore, it highlights their potential use in treating diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.
Career Highlights
Chris Adair is currently employed at Novartis AG, a leading global healthcare company. His role involves extensive research and development in the pharmaceutical sector, where he applies his expertise to create effective therapeutic solutions. His contributions have been instrumental in advancing the company's mission to improve health outcomes worldwide.
Collaborations
Chris has collaborated with esteemed colleagues, including Yuko Isome and Jian Ding. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas, ultimately leading to groundbreaking advancements in their field.
Conclusion
In summary, Chris Adair is a dedicated inventor whose work in pharmaceutical chemistry has led to significant advancements in medical treatments. His innovative approach and collaboration with talented colleagues continue to drive progress in the industry.